Editor's Note: At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Ida Wong-Sefidan (MD) from the AIDS Malignancy Consortium (AMC), on behalf of the research team, shared a milestone study. This study aimed to evaluate the clinical benefits of the Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib in combination with dose-adjusted R-EPOCH (R-da-EPOCH) for the treatment of Human Immunodeficiency Virus-associated Diffuse Large B-cell Lymphoma (HIV-DLBCL). The study results not only confirmed the safety of the regimen but also provided critical data support in terms of efficacy and subgroup survival analysis.01 Background & Challenges: Current Status and Breakthrough Points in the Diagnosis and Treatment of HIV-Associated DLBCL
Lymphoma is one of the most common malignancies among people living with Human Immunodeficiency Virus (HIV). Statistics show that approximately 10% of HIV-infected individuals may develop lymphoma during their lifetime. Among these, Diffuse Large B-cell Lymphoma (DLBCL) is the primary pathological type. Over the past few decades, with the widespread use of highly active antiretroviral therapy (ART) and the application of the dose-adjusted R-EPOCH regimen, the survival rate of HIV-DLBCL patients has significantly improved, gradually approaching that of the non-HIV population. However, HIV-associated DLBCL still exhibits stronger aggressiveness. Clinical observations indicate that this population has a high rate of central nervous system (CNS) involvement, and the recurrence rate cannot be ignored. Furthermore, the immunosuppressive state brought by HIV infection and co-infections (such as EBV, HHV-8, etc.) makes the molecular subtypes (such as GCB and ABC subtypes) of this group more complex than those in the non-HIV population. Finding an integrated regimen that further enhances efficacy based on standard immunochemotherapy (R-da-EPOCH) without increasing toxicity is a key research direction in the current field of hematologic oncology.
02 Mechanism of Action: Why Choose to Integrate BTK Inhibitors into Chemotherapy?
BTK is a core kinase in the B-cell receptor (BCR) signaling pathway. In the non-germinal center B-cell-like (non-GCB/ABC) subtype of DLBCL, continuous activation of the BCR signaling pathway is key to driving tumor growth. The previous Phoenix study attempted to add Ibrutinib to the R-CHOP regimen. Although no overall survival (OS) benefit was observed in the general population, a significant survival advantage was shown in patients under 60 years old and in specific molecular subtypes (such as MCD and N1 subtypes). Notably, previous large-scale clinical studies like Phoenix usually excluded HIV-positive patients, leading to a lack of efficacy data for Ibrutinib in this special group. Professor Wong-Sefidan pointed out that the logic for integrating Ibrutinib is based on the following three points:
- Molecular Characteristics: HIV-DLBCL contains a large number of non-GCB subtypes, which have potential sensitivity to BTK inhibition.
- Potential Antiviral Effect: Research has found that HIV-infected cells have a certain sensitivity to BTK inhibition, and Ibrutinib may inhibit ITK during T-cell receptor activation, thereby regulating the immune environment.
- Synergistic Effect: The combination of BTK inhibitors and chemotherapy may produce synergistic anti-tumor effects by targeting biological characteristics of different pathways.
03 Study Design: Rigorous Layout and Enrollment Criteria of the AMC-095 Trial
This study is a multicenter Phase 1/2 trial led by the AMC and conducted at 12 sites across the United States. • Inclusion Criteria: Patients must be HIV-positive and diagnosed with DLBCL. The study had no lower limit requirement for CD4+ T cell counts (in the dose-expansion cohort). Exclusion criteria were particularly strict, focusing on drug-drug interactions (DDI): patients were prohibited from using strong or moderate CYP3A4 inhibitors, including some antiretroviral drugs and certain antifungal drugs (such as azoles), as they would significantly increase the blood concentration of Ibrutinib and increase toxicity. • Treatment Regimen: o Phase 1 (3+3 Design): To determine the optimal dose of Ibrutinib, ultimately confirmed as 560mg/day. o Phase 2: Patients received Ibrutinib (560mg, days 1-25) combined with the R-da-EPOCH regimen. o Process: Patients underwent CT assessment after completing 4 cycles of treatment. If a complete response (CR) or partial response (PR) was achieved, they continued to complete a total of 6 cycles of treatment. A final PET-CT evaluation was performed after the end of treatment.
04 Safety & Tolerability: Manageable Toxicity Profiles
Among the 43 patients evaluable for safety, the study showed that Ibrutinib combined with R-da-EPOCH was well-tolerated. • Dose Intensity: The actual number of dosing days for Ibrutinib within a median 21-day cycle was 17 days. The median number of completed treatment cycles was 5. • Adverse Events (AEs): The observed AEs were mostly consistent with the expected toxicities of Ibrutinib and standard immunochemotherapy. o Hematological Toxicity: Primarily manifested as myelosuppression, such as neutropenia. o Non-hematological Toxicity: Gastrointestinal discomfort, nausea, and infections were more common. o Serious AEs: One case of duodenal perforation was recorded, attributed to tumor lymph node necrosis involving the intestinal wall. Four patients discontinued treatment due to AEs (including long-term cytopenia, enteritis, and severe nausea). • Conclusion: Under the premise of strict screening for CYP3A4 interacting drugs, Ibrutinib 560mg/day combined with R-da-EPOCH is safe and feasible in the HIV population.
05 Efficacy Analysis: Remarkable 100% Objective Response Rate
Among the 38 patients evaluable for efficacy, the study results demonstrated extremely high clinical response intensity: • Objective Response Rate (ORR): 100%. • Depth of Response: 58% of patients achieved complete response (CR), and 42% of patients achieved partial response (PR). It should be noted that because the interim assessment of the Phase 2 stage mainly used CT rather than PET-CT, the CR rate might be underestimated. • Follow-up Data: The median follow-up time was 4.2 years, and the median duration of response (DoR) was 2.8 years. • Recurrence Status: Only 6 patients experienced disease progression or recurrence during the follow-up period (including 1 patient who was originally CR and 5 who were originally PR).
06 Survival Data and Biomarker Exploration: Breaking Traditional COO Predictive Value
The study conducted an in-depth exploration of survival benefits and biomarkers, revealing characteristics different from the non-HIV population: • Survival Rate Data: o 1-year Progression-Free Survival (PFS) rate: 89%. o 2-year Progression-Free Survival (PFS) rate: 83%. o 1-year Overall Survival (OS) rate: 92%. o 2-year Overall Survival (OS) rate: 85%. • Cell of Origin (COO) Analysis: Through immunohistochemistry (IHC) typing, it was found that regardless of whether patients were GCB or non-GCB subtype, there was no statistically significant difference in their response rates and survival rates (PFS/OS) (P-values did not reach statistical significance). This suggests that under the high-intensity regimen of Ibrutinib combined with R-da-EPOCH, subtypes that traditionally predict poor efficacy obtained equal benefits. • Influence of Other Factors: EBV infection status and baseline CD4+ T cell counts (high or low) also had no significant impact on survival benefits. • Significance of BCL-6: Expression of the BCL-6 protein was positively correlated with the CR rate but did not translate into statistically significant differences in long-term survival (PFS/OS).
Summary and Outlook: Opening a New Therapeutic Strategy for HIV-DLBCL
The AMC-095 study proves that integrating Ibrutinib into the R-da-EPOCH regimen for the treatment of HIV-associated DLBCL is an extremely successful strategy. The study not only achieved a 100% ORR but also showed 2-year PFS (83%) and 2-year OS (85%) data that are superior to the concurrent data of using R-da-EPOCH alone in previous AMC studies (previous 2-year data was approximately in the 70% range). Professor Ida Wong-Sefidan concluded that this integrated regimen has shown excellent long-term survival protection in the highly aggressive HIV-associated DLBCL population, and the toxicity is preventable and controllable. Future research directions will further utilize gene expression profiling (GEP) and deeper molecular typing to explore the optimal population that can benefit from BTK inhibitors in HIV-DLBCL, providing more evidence for precision treatment of HIV-associated malignancies.
